Brokerages expect that Tandem Diabetes Care Inc (NASDAQ:TNDM) will announce earnings of ($0.08) per share for the current fiscal quarter, according to Zacks. Five analysts have made estimates for Tandem Diabetes Care’s earnings. The highest EPS estimate is $0.06 and the lowest is ($0.21). Tandem Diabetes Care posted earnings of $0.02 per share during the same quarter last year, which would indicate a negative year over year growth rate of 500%. The company is scheduled to issue its next quarterly earnings report on Tuesday, February 25th.
On average, analysts expect that Tandem Diabetes Care will report full year earnings of ($0.58) per share for the current year, with EPS estimates ranging from ($0.68) to ($0.41). For the next year, analysts expect that the business will post earnings of $0.02 per share, with EPS estimates ranging from ($0.30) to $0.50. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that follow Tandem Diabetes Care.
Tandem Diabetes Care (NASDAQ:TNDM) last posted its quarterly earnings data on Monday, November 4th. The medical device company reported ($0.13) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.20) by $0.07. The business had revenue of $94.66 million during the quarter, compared to analysts’ expectations of $88.46 million. Tandem Diabetes Care had a negative return on equity of 9.44% and a negative net margin of 7.19%.
A number of equities analysts have weighed in on the stock. UBS Group upgraded shares of Tandem Diabetes Care from a “neutral” rating to a “buy” rating and set a $75.00 price objective for the company in a research report on Friday, October 4th. BidaskClub raised shares of Tandem Diabetes Care from a “hold” rating to a “buy” rating in a report on Saturday, November 23rd. Guggenheim started coverage on shares of Tandem Diabetes Care in a research report on Thursday, October 17th. They set a “buy” rating and a $76.00 price target for the company. Finally, ValuEngine downgraded shares of Tandem Diabetes Care from a “sell” rating to a “strong sell” rating in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and twelve have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $75.31.
In related news, CEO John F. Sheridan sold 462 shares of the company’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $70.00, for a total transaction of $32,340.00. Following the completion of the sale, the chief executive officer now owns 2,963 shares of the company’s stock, valued at approximately $207,410. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO John F. Sheridan sold 9,538 shares of the stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $70.03, for a total transaction of $667,946.14. Following the completion of the sale, the chief executive officer now owns 12,039 shares of the company’s stock, valued at approximately $843,091.17. The disclosure for this sale can be found here. Insiders sold 45,000 shares of company stock valued at $2,988,036 over the last quarter. Company insiders own 6.90% of the company’s stock.
Institutional investors have recently modified their holdings of the company. Nisa Investment Advisors LLC lifted its position in Tandem Diabetes Care by 53.3% during the second quarter. Nisa Investment Advisors LLC now owns 460 shares of the medical device company’s stock worth $30,000 after buying an additional 160 shares in the last quarter. TRUE Private Wealth Advisors purchased a new position in shares of Tandem Diabetes Care during the 2nd quarter worth $33,000. First Quadrant L P CA acquired a new position in shares of Tandem Diabetes Care during the 3rd quarter valued at about $34,000. James Investment Research Inc. boosted its position in shares of Tandem Diabetes Care by 15.9% during the 2nd quarter. James Investment Research Inc. now owns 1,315 shares of the medical device company’s stock valued at $85,000 after acquiring an additional 180 shares during the last quarter. Finally, Stephens Inc. AR purchased a new stake in shares of Tandem Diabetes Care in the second quarter valued at about $113,000. Institutional investors and hedge funds own 83.16% of the company’s stock.
Shares of NASDAQ:TNDM traded down $1.86 during midday trading on Friday, reaching $61.88. 1,593,984 shares of the company’s stock traded hands, compared to its average volume of 1,614,355. The company has a fifty day simple moving average of $64.06 and a two-hundred day simple moving average of $64.13. Tandem Diabetes Care has a 1 year low of $29.43 and a 1 year high of $74.81. The company has a market cap of $3.77 billion, a P/E ratio of -24.27 and a beta of 0.23. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.05 and a current ratio of 2.46.
Tandem Diabetes Care Company Profile
Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.
Read More: What does earnings per share mean?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.